Immune Checkpoints Activators 2018 - Competitive Landscape, Technology and Pipeline Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report provides the detailed analysis of 80+ products along with 45+ companies involved. Memgen has been granted Orphan drug designation from US-FDA for ISF 35 for the treatment of stage IIb through IV melanoma.

Products Covered by Phase

  • Phase II and Phase I
  • Pre-clinical and Discovery
  • Inactive (Dormant and Discontinued)

Scope

  • The report provides competitive pipeline landscape of Immune Checkpoints Activators
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Immune Checkpoints Activators
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Mentioned

  • AbbVie
  • Abeome Corporation
  • Alligator Bioscience AB
  • Alpine Immune Sciences
  • Amgen
  • AP Biosciences
  • Apogenix
  • BioInvent
  • Bristol-Myers Squibb
  • Celldex
  • Crystal Bioscience
  • Daiichi Sankyo
  • DNAtrix
  • Five Prime Therapeutics
  • Genentech
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Janssen Biotech
  • MedImmune
  • Memgen
  • Merck
  • Moderna Therapeutics
  • Nanjing Galaxy Biopharmaceutical
  • Nektar Therapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Pieris Pharmaceuticals
  • rEVO Biologics
  • Roche
  • Sanofi
  • Seattle Genetics
  • Sorrento Therapeutics
  • TheraMAB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c8n6b5/immune?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs